The initial public offer (IPO) of Aptus Pharma received bids for 23,72,000 shares as against 13,32,000 shares on offer, as per BSE data as of 17:00 hours on Tuesday (23 September 2025). The issue was subscribed 1.78 times.
The issue opened for bidding on Tuesday (23 September 2025) and it will close on Thursday (25 September 2025). The price band of the IPO is fixed between Rs 65 to 70 per share. The minimum order quantity is 2,000 equity shares. The equity shares will list on BSE’s SME platform.
The IPO comprises fresh issue of 18,60,000 equity shares. The promoter and promoter group shareholding will dilute to 72.89% from 100% pre-issue.
About 94,000 equity shares will be reserved for subscription by market maker to the issue. The net issue comprises of 17,66,000 equity shares. The public issue and net issue will constitute 27.11% and 25.74% respectively of the post- issue paid-up equity share capital of the company.
The company intends to utilize the net proceeds for capital expenditure for office premises with furniture and industrial racks, working capital and general corporate purpose.
Ahead of the IPO, Aptus Pharma on Monday, 22 September 2025, raised Rs 1 crore from anchor investors. The board allotted 1.44 lakh shares at Rs 70 each to 3 anchor investors.
Aptus Pharma is engaged in the marketing and distribution of finished pharmaceutical formulations. The company operates through a contract manufacturing model and does not own any manufacturing facilities. It has contract manufacturing agreements with seven manufacturing units, including formal loan and license agreements with two units. The remaining production is managed through informal arrangements based on purchase orders.
It offers a diverse range of pharmaceutical products across various therapeutic categories, including anti-infectives, gastrointestinal, antacids, anti-allergic and respiratory, nutritional supplements, pain management, neuro-psychiatric, cardiovascular, anti-diabetic, lipid-lowering, and general wellness. These products are available in multiple dosage forms such as tablets, capsules, softgels, syrups, suspensions, injections, ointments, creams, balms, drops, lotions, vials, powders, gels, and sachets. As of 31 May 2025, the company had total 70 employees.
The company recorded revenue from operations of Rs 24.56 crore and net profit of Rs 3.10 crore for the year ended 31 March 2025.